Antibody Information
General Information of This Antibody
| Antibody ID | ANI0RTCZD |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | A humanized IgG1 monoclonal antibody targeting CLDN18.2 |
|||||
| Synonyms |
a humanized IgG1 monoclonal antibody targeting CLDN18.2
Click to Show/Hide
|
|||||
| Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SHR-A1904 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05277168 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, single-arm, multi-center phase 1/2a clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in subjects with advanced solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04928625 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in patients with advanced pancreatic cancer.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04877717 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in patients with advanced solid tumors.
|
||||
References